Peginterferon beta-1a is a new treatment for relapsing-remitting multiple sclerosis (RRMS) with the advantage of a more convenient, low frequency, subcutaneous (SC) dosing regimen compared with other beta interferons [1, 2]. This evidence concerns the gene GDI1 and relapsing-remitting multiple sclerosis.